Publicaciones en las que colabora con MARÍA ÁNGELES MORO SÁNCHEZ (28)

2024

  1. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline

    British Journal of Pharmacology

2023

  1. Comparison of 2 medium cutoff dialyzers versus on-line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research

    Artificial Organs, Vol. 47, Núm. 3, pp. 589-594

  2. Defective hippocampal neurogenesis underlies cognitive impairment by carotid stenosis-induced cerebral hypoperfusion in mice

    Frontiers in Cellular Neuroscience, Vol. 17

  3. Ipsilesional Hippocampal GABA Is Elevated and Correlates With Cognitive Impairment and Maladaptive Neurogenesis After Cortical Stroke in Mice

    Stroke, Vol. 54, Núm. 10, pp. 2652-2665

  4. Saturated fatty acid-enriched small extracellular vesicles mediate a crosstalk inducing liver inflammation and hepatocyte insulin resistance

    JHEP Reports, Vol. 5, Núm. 8

2022

  1. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

    Molecular Therapy - Nucleic Acids, Vol. 28, pp. 124-135

2021

  1. Effective glutamate clearance from the systemic circulation by hemodialysis: Potential relevance for cerebral ischemia management

    Artificial Organs, Vol. 45, Núm. 10, pp. 1183-1188

  2. Influence of metabolic syndrome on post-stroke outcome, angiogenesis and vascular function in old rats determined by dynamic contrast enhanced MRI

    Journal of Cerebral Blood Flow and Metabolism, Vol. 41, Núm. 7, pp. 1692-1706

2019

  1. Abolition of aberrant neurogenesis ameliorates cognitive impairment after stroke in mice

    Journal of Clinical Investigation, Vol. 129, Núm. 4, pp. 1536-1550

2018

  1. AhR deletion promotes aberrant morphogenesis and synaptic activity of adult-generated granule neurons and impairs hippocampus-dependent memory

    eNeuro, Vol. 5, Núm. 4

  2. TLR4-Binding DNA Aptamers Show a Protective Effect against Acute Stroke in Animal Models

    Molecular Therapy, Vol. 26, Núm. 8, pp. 2047-2059

2017

  1. Cannabinoid type-2 receptor drives neurogenesis and improves functional outcome after stroke

    Stroke, Vol. 48, Núm. 1, pp. 204-212

2015

  1. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications

    Neurotherapeutics, Vol. 12, Núm. 4, pp. 793-806

2013

  1. Amelioration of Ischemic brain damage by peritoneal dialysis

    Journal of Clinical Investigation, Vol. 123, Núm. 10, pp. 4359-4363

2012

  1. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection

    Stroke, Vol. 43, Núm. 1, pp. 211-219

  2. Daidzein has neuroprotective effects through ligand-binding-independent PPARγ activation

    Neurochemistry International, Vol. 61, Núm. 1, pp. 119-127

2011

  1. Longitudinal studies of ischemic penumbra by using 18F-FDG PET and MRI techniques in permanent and transient focal cerebral ischemia in rats

    NeuroImage, Vol. 57, Núm. 1, pp. 45-54

2006

  1. Rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J 2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms

    Journal of Cerebral Blood Flow and Metabolism, Vol. 26, Núm. 2, pp. 218-229

2005

  1. The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke

    Journal of Neuropathology and Experimental Neurology, Vol. 64, Núm. 9, pp. 797-805

2003

  1. Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain

    Neuropsychopharmacology, Vol. 28, Núm. 9, pp. 1579-1588